The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product ...

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

GSK has reached a $2.2bn settlement to resolve the vast majority of cases linked to its heartburn medicine Zantac, in a move that will help assuage legal concerns overhanging the UK drugmaker.

(Alliance News) - GSK PLC on Wednesday agreed to pay up to USD2.2 billion to settle the vast majority of cases linked to its heartburn medicine Zantac.

GSK (GSK) on Wednesday announced a settlement resolving a bundle of 80,000 product liability cases in the US that alleged its over-the-counter heartburn medication, Zantac, increased the risk of ...

GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...